Acurx Pharmaceuticals (ACXP) News Today $0.43 0.00 (-0.14%) As of 11:42 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACXP Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Acurx Pharmaceuticals files $50M mixed shelf offeringJuly 9, 2025 | msn.comAcurx Pharmaceuticals Inc Ordinary Shares ACXP - MorningstarJuly 2, 2025 | morningstar.comMAcurx Pharmaceuticals LLC (ACXP) - Investing.comJuly 2, 2025 | investing.com/C O R R E C T I O N -- Acurx Pharmaceuticals, Inc./ | ACXP Stock NewsJune 18, 2025 | gurufocus.comAcurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2. ...June 17, 2025 | gurufocus.comAcurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross ProceedsJune 17, 2025 | investing.comAcurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross ProceedsJune 17, 2025 | prnewswire.comAcurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDIJune 17, 2025 | prnewswire.comAcurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific ConferenceJune 9, 2025 | prnewswire.comEarnings call transcript: Acurx Pharmaceuticals beats Q1 2025 EPS forecastMay 14, 2025 | uk.investing.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comAcurx Pharmaceuticals, Inc. (ACXP) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comAcurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update | ACXP ...May 13, 2025 | gurufocus.comAcurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business UpdateMay 13, 2025 | prnewswire.comA Look Ahead: Acurx Pharmaceuticals's Earnings ForecastMay 12, 2025 | benzinga.comAcurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business UpdateApril 30, 2025 | prnewswire.comAcurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company ShowcaseApril 28, 2025 | prnewswire.comAcurx granted new patent for DNA Polymerase IIIC InhibitorsApril 18, 2025 | markets.businessinsider.comIndian Patent Office Grants Acurx Patent for DNA Polymerase IIIC InhibitorsApril 17, 2025 | prnewswire.comNew to The Street Renews Acurx Pharmaceuticals for Exclusive 6-Month Media Series Including Nationwide TV, Earned Media, and Expanded Digital ReachApril 17, 2025 | finanznachrichten.deAcurx files to sell 8.4M shares of common stock for holdersApril 5, 2025 | markets.businessinsider.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2024 Earnings Call TranscriptMarch 19, 2025 | msn.comAcurx reports Q4 EPS (16c) vs. (37c) last yearMarch 18, 2025 | markets.businessinsider.comAcurx price target lowered to $5 from $14 at Alliance Global PartnersMarch 18, 2025 | markets.businessinsider.comAcurx Pharmaceuticals, Inc. (ACXP) Q4 2024 Earnings Call TranscriptMarch 18, 2025 | seekingalpha.comAcurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business UpdateMarch 18, 2025 | prnewswire.comAcurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct OfferingMarch 10, 2025 | gurufocus.comAcurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct OfferingMarch 10, 2025 | investing.comAcurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct OfferingMarch 10, 2025 | prnewswire.comAcurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct OfferingMarch 7, 2025 | gurufocus.comAcurx to sell 2.745M shares at 40c in registered direct offeringMarch 7, 2025 | markets.businessinsider.comAcurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct OfferingMarch 7, 2025 | prnewswire.comAcurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI AntibioticsMarch 3, 2025 | prnewswire.comAcurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business UpdateFebruary 28, 2025 | prnewswire.comAcurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDIFebruary 24, 2025 | prnewswire.comAcurx new patent granted by JPO related to DNA Polymerase IIIC InhibitorsFebruary 19, 2025 | markets.businessinsider.comJPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC InhibitorsFebruary 19, 2025 | prnewswire.comAcurx files to sell 2.61M shares of common stock for holdersJanuary 31, 2025 | markets.businessinsider.comAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Director Joseph C. Scodari Buys 24,631 SharesJanuary 9, 2025 | insidertrades.comAcurx receives positive EMA guidance for ibezapolstat Phase 3 programJanuary 7, 2025 | markets.businessinsider.comAcurx to sell 2.46M shares at $1.015 in registered direct offeringJanuary 7, 2025 | markets.businessinsider.comAcurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJanuary 7, 2025 | prnewswire.comAcurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJanuary 6, 2025 | investing.comAcurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJanuary 6, 2025 | prnewswire.comAcurx Pharmaceuticals, Inc.: Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)January 6, 2025 | finanznachrichten.deAcurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)January 6, 2025 | prnewswire.comOptimistic Buy Rating for Acurx Pharmaceuticals Driven by Promising Ibezapolstat Progress and Strategic Financial PlanningDecember 12, 2024 | markets.businessinsider.comAcurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA CommunicationsDecember 9, 2024 | prnewswire.comAcurx Pharmaceuticals (NASDAQ:ACXP) Stock, Insider Trading ActivityNovember 22, 2024 | benzinga.comAcurx Pharmaceuticals Shares Slide 17% After Disclosing Bitcoin InvestmentNovember 20, 2024 | marketwatch.com Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Email Address ACXP Media Mentions By Week ACXP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACXP News Sentiment▼0.940.97▲Average Medical News Sentiment ACXP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACXP Articles This Week▼21▲ACXP Articles Average Week Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Pluri News Prelude Therapeutics News Mural Oncology News Actinium Pharmaceuticals News Scilex News Grace Therapeutics News Exicure News Acrivon Therapeutics News PepGen News Shattuck Labs News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACXP) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredMajor Rollout of Social Security X?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredThe Next Commodity Crisis Just Got a Name: SilverElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACXP Stock Alerts